Nanoparticle-based biosensor integrated with multiple cross-displacement amplification for visual and rapid identification of hepatitis B virus and hepatitis C virus

• DOI: 10.1128/spectrum.01738-24
• Publication Date: 2025-04-15T11:23:01Z
• Authors: Hang Zhang; Yuanfang Shi; Zengguang Wu; Qi Zhao; Yu Wang; Xinggui Yang; Yan Tan; Yi Wang; Zhenghua Xiao; Xu Chen

ABSTRACT Infection with hepatitis B virus (HBV) and C (HCV) is a major contributor to liver-related morbidity mortality worldwide. An accurate rapid point-of-care (POC) diagnostic approach the gateway for effective treatment control of these infections. Here, first time, we integrated isothermal multiple cross-displacement amplification (MCDA) gold nanoparticle-based lateral flow biosensor (AuNPs-LFB) successfully develop novel HBV&HCV-MCDA-AuNPs-LFB assay simultaneous accurate, sensitive, rapid, inexpensive, visual identification HBV HCV agents. The two unique sets MCDA degenerate primers were designed targeting S 5′ untranslated region (5′-UTR) genes from genotypes (B, C, D, B/C recombinant, C/D recombinant) subtypes in China (1b, 2a, 3a, 3b, 6a), respectively. optimal conditions reaction confirmed be 64°C 35 min. products decoded visually using AuNPs-LFB platform, which was devised analyzing three targets, including HBV-MCDA, HCV-MCDA amplicons, chromatography control. whole detection procedure, nucleic acid extraction (~10 min), (35 AuNPs‐LFB interpretation (~2 can completed within 50 detect target (HBV- HCV-5′-UTR) as low 10 copies gene-containing plasmid template per test does not cross-react other pathogens. Therefore, our preliminary results indicated that developed this study potentially serve useful POC tool IMPORTANCE Hepatitis infections have been regarded by World Health Organization threats human health, especially low- middle-income regions. Underdiagnosis HBV/HCV particular challenge achieving Organization’s goal eliminating 2030. differentiation